메뉴 건너뛰기




Volumn 112, Issue 8, 2017, Pages 751-758

Corrigendum to: High platelet content can increase storage lesion rates following Intercept pathogen inactivation primarily in platelet concentrates prepared by apheresis (Vox Sanguinis, (2017), 112, 8, (751-758), 10.1111/vox.12596);High platelet content can increase storage lesion rates following Intercept pathogen inactivation primarily in platelet concentrates prepared by apheresis

Author keywords

pathogen inactivation; platelets; quality control

Indexed keywords

GLUCOSE; LACTIC ACID; LIPOCORTIN 5; NONOXINOL 9; PADGEM PROTEIN; THROMBOCYTE CONCENTRATE;

EID: 85032912722     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/vox.12714     Document Type: Erratum
Times cited : (13)

References (24)
  • 1
    • 84962471476 scopus 로고    scopus 로고
    • Assays for quality control of platelets for transfusion
    • Deckmyn H, Feys HB: Assays for quality control of platelets for transfusion. ISBT Sci Ser 2013; 8:221–224
    • (2013) ISBT Sci Ser , vol.8 , pp. 221-224
    • Deckmyn, H.1    Feys, H.B.2
  • 2
    • 84927558924 scopus 로고    scopus 로고
    • In vitro evaluation of pathogen-inactivated buffy coat-derived platelet concentrates during storage: psoralen-based photochemical treatment step-by-step
    • Abonnenc M, Sonego G, Kaiser-Guignard J, et al.: In vitro evaluation of pathogen-inactivated buffy coat-derived platelet concentrates during storage: psoralen-based photochemical treatment step-by-step. Blood Transfus 2015; 13:255–264
    • (2015) Blood Transfus , vol.13 , pp. 255-264
    • Abonnenc, M.1    Sonego, G.2    Kaiser-Guignard, J.3
  • 3
    • 3142592149 scopus 로고    scopus 로고
    • Implementation of the INTERCEPT Blood System for platelets into routine blood bank manufacturing procedures: evaluation of apheresis platelets
    • Janetzko K, Lin L, Eichler H, et al.: Implementation of the INTERCEPT Blood System for platelets into routine blood bank manufacturing procedures: evaluation of apheresis platelets. Vox Sang 2004; 86:239–245
    • (2004) Vox Sang , vol.86 , pp. 239-245
    • Janetzko, K.1    Lin, L.2    Eichler, H.3
  • 4
    • 33947365171 scopus 로고    scopus 로고
    • In vitro evaluation of metabolic changes and residual platelet responsiveness in photochemical treated and gamma-irradiated single-donor platelet concentrates during long-term storage
    • Apelseth TO, Bruserud O, Wentzel-Larsen T, et al.: In vitro evaluation of metabolic changes and residual platelet responsiveness in photochemical treated and gamma-irradiated single-donor platelet concentrates during long-term storage. Transfusion 2007; 47:653–665
    • (2007) Transfusion , vol.47 , pp. 653-665
    • Apelseth, T.O.1    Bruserud, O.2    Wentzel-Larsen, T.3
  • 5
    • 84927910657 scopus 로고    scopus 로고
    • Riboflavin and amotosalen photochemical treatments of platelet concentrates reduce thrombus formation kinetics in vitro
    • Van Aelst B, Feys HB, Devloo R, et al.: Riboflavin and amotosalen photochemical treatments of platelet concentrates reduce thrombus formation kinetics in vitro. Vox Sang 2015; 108:328–339
    • (2015) Vox Sang , vol.108 , pp. 328-339
    • Van Aelst, B.1    Feys, H.B.2    Devloo, R.3
  • 6
    • 84995810432 scopus 로고    scopus 로고
    • Psoralen and ultraviolet a light treatment directly affects phosphatidylinositol 3-kinase signal transduction by altering plasma membrane packing
    • Van Aelst B, Devloo R, Zachee P, et al.: Psoralen and ultraviolet a light treatment directly affects phosphatidylinositol 3-kinase signal transduction by altering plasma membrane packing. J Biol Chem 2016; 291:24364–24376
    • (2016) J Biol Chem , vol.291 , pp. 24364-24376
    • Van Aelst, B.1    Devloo, R.2    Zachee, P.3
  • 7
    • 0037443546 scopus 로고    scopus 로고
    • Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial
    • van Rhenen D, Gulliksson H, Cazenave JP, et al.: Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003; 101:2426–2433
    • (2003) Blood , vol.101 , pp. 2426-2433
    • van Rhenen, D.1    Gulliksson, H.2    Cazenave, J.P.3
  • 8
    • 4444380592 scopus 로고    scopus 로고
    • Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial
    • McCullough J, Vesole DH, Benjamin RJ, et al.: Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood 2004; 104:1534–1541
    • (2004) Blood , vol.104 , pp. 1534-1541
    • McCullough, J.1    Vesole, D.H.2    Benjamin, R.J.3
  • 9
    • 85026448014 scopus 로고    scopus 로고
    • Pathogen-reduced platelets for the prevention of bleeding
    • Butler C, Doree C, Estcourt LJ, et al.: Pathogen-reduced platelets for the prevention of bleeding. Cochrane Database Syst Rev 2013; 3:CD009072
    • (2013) Cochrane Database Syst Rev , vol.3 , pp. CD009072
    • Butler, C.1    Doree, C.2    Estcourt, L.J.3
  • 10
    • 85007305879 scopus 로고    scopus 로고
    • Experiences with semi-routine production of riboflavin and UV-B pathogen-inactivated platelet concentrates in three blood centres
    • van der Meer PF, Couture C, Hervig T, et al.: Experiences with semi-routine production of riboflavin and UV-B pathogen-inactivated platelet concentrates in three blood centres. Vox Sang 2017; 112:9–17
    • (2017) Vox Sang , vol.112 , pp. 9-17
    • van der Meer, P.F.1    Couture, C.2    Hervig, T.3
  • 11
    • 79956057782 scopus 로고    scopus 로고
    • Blood processing
    • Hardwick J: Blood processing. ISBT Sci Ser 2008; 3:148–176
    • (2008) ISBT Sci Ser , vol.3 , pp. 148-176
    • Hardwick, J.1
  • 12
    • 21644481801 scopus 로고    scopus 로고
    • Flow-cytometric analysis of platelet-membrane glycoprotein expression and platelet activation
    • Goodall AH, Appleby J: Flow-cytometric analysis of platelet-membrane glycoprotein expression and platelet activation. Methods Mol Biol 2004; 272:225–253
    • (2004) Methods Mol Biol , vol.272 , pp. 225-253
    • Goodall, A.H.1    Appleby, J.2
  • 13
    • 79851505189 scopus 로고    scopus 로고
    • Pathogen inactivation of platelet and plasma blood components for transfusion using the INTERCEPT Blood System
    • Irsch J, Lin L: Pathogen inactivation of platelet and plasma blood components for transfusion using the INTERCEPT Blood System. Transfus Med Hemother 2011; 38:19–31
    • (2011) Transfus Med Hemother , vol.38 , pp. 19-31
    • Irsch, J.1    Lin, L.2
  • 14
    • 78651329604 scopus 로고    scopus 로고
    • In vitro assessment of apheresis and pooled buffy coat platelet components suspended in plasma and SSP+ photochemically treated with amotosalen and UVA for pathogen inactivation (INTERCEPT Blood System™)
    • Chavarin P, Cognasse F, Argaud C, et al.: In vitro assessment of apheresis and pooled buffy coat platelet components suspended in plasma and SSP+ photochemically treated with amotosalen and UVA for pathogen inactivation (INTERCEPT Blood System™). Vox Sang 2011; 100:247–249
    • (2011) Vox Sang , vol.100 , pp. 247-249
    • Chavarin, P.1    Cognasse, F.2    Argaud, C.3
  • 15
    • 12844263481 scopus 로고    scopus 로고
    • In vitro evaluation of COM.TEC apheresis platelet concentrates using a preparation set and pathogen inactivation over a storage period of five days
    • Moog R, Frohlich A, Mayaudon V, et al.: In vitro evaluation of COM.TEC apheresis platelet concentrates using a preparation set and pathogen inactivation over a storage period of five days. J Clin Apher 2004; 19:185–191
    • (2004) J Clin Apher , vol.19 , pp. 185-191
    • Moog, R.1    Frohlich, A.2    Mayaudon, V.3
  • 16
    • 67650458193 scopus 로고    scopus 로고
    • Functional characteristics of apheresis-derived platelets treated with ultraviolet light combined with either amotosalen-HCl (S-59) or riboflavin (vitamin B2) for pathogen-reduction
    • Picker SM, Oustianskaia L, Schneider V, et al.: Functional characteristics of apheresis-derived platelets treated with ultraviolet light combined with either amotosalen-HCl (S-59) or riboflavin (vitamin B2) for pathogen-reduction. Vox Sang 2009; 97:26–33
    • (2009) Vox Sang , vol.97 , pp. 26-33
    • Picker, S.M.1    Oustianskaia, L.2    Schneider, V.3
  • 17
    • 33644899119 scopus 로고    scopus 로고
    • In vitro evaluation of Haemonetics MCS+ apheresis platelet concentrates treated with photochemical pathogen inactivation following plasma volume reduction using the INTERCEPT Preparation Set
    • Isola H, Kientz D, Aleil B, et al.: In vitro evaluation of Haemonetics MCS+ apheresis platelet concentrates treated with photochemical pathogen inactivation following plasma volume reduction using the INTERCEPT Preparation Set. Vox Sang 2006; 90:128–130
    • (2006) Vox Sang , vol.90 , pp. 128-130
    • Isola, H.1    Kientz, D.2    Aleil, B.3
  • 18
    • 0029068284 scopus 로고
    • A comparative study in volunteers of apheresis and buffy coat derived platelets
    • Mitchell SG, Turner VS, Hawker RJ, et al.: A comparative study in volunteers of apheresis and buffy coat derived platelets. Platelets 1995; 6:146–151
    • (1995) Platelets , vol.6 , pp. 146-151
    • Mitchell, S.G.1    Turner, V.S.2    Hawker, R.J.3
  • 19
    • 0034059106 scopus 로고    scopus 로고
    • Are all leucodepleted platelet concentrates equivalent?
    • Krailadsiri P, Seghatchian J: Are all leucodepleted platelet concentrates equivalent? Vox Sang 2000; 78:171–175
    • (2000) Vox Sang , vol.78 , pp. 171-175
    • Krailadsiri, P.1    Seghatchian, J.2
  • 20
    • 77958469821 scopus 로고    scopus 로고
    • Function and activation state of platelets in vitro depend on apheresis modality
    • Macher S, Sipurzynski-Budraß S, Rosskopf K, et al.: Function and activation state of platelets in vitro depend on apheresis modality. Vox Sang 2010; 99:332–340
    • (2010) Vox Sang , vol.99 , pp. 332-340
    • Macher, S.1    Sipurzynski-Budraß, S.2    Rosskopf, K.3
  • 21
    • 62949235839 scopus 로고    scopus 로고
    • Cell integrity and mitochondrial function after Mirasol-PRT treatment for pathogen reduction of apheresis-derived platelets: results of a three-arm in vitro study
    • Picker SM, Steisel A, Gathof BS: Cell integrity and mitochondrial function after Mirasol-PRT treatment for pathogen reduction of apheresis-derived platelets: results of a three-arm in vitro study. Transfus Apher Sci 2009; 40:79–85
    • (2009) Transfus Apher Sci , vol.40 , pp. 79-85
    • Picker, S.M.1    Steisel, A.2    Gathof, B.S.3
  • 22
    • 85032931266 scopus 로고    scopus 로고
    • In-vivo and in-vitro evaluation of stored platelet products
    • in, Lozano M, Sweeney JD, (eds), Bethesda, MD, AABB Press
    • Heaton WA: In-vivo and in-vitro evaluation of stored platelet products; in Lozano M, Sweeney JD (eds): Platelet Transfusion Therapy. Bethesda, MD, AABB Press, 2013:177–227
    • (2013) Platelet Transfusion Therapy , pp. 177-227
    • Heaton, W.A.1
  • 23
    • 0036795689 scopus 로고    scopus 로고
    • Platelet concentrates derived from buffy coat and apheresis: biochemical and functional differences
    • Böck M, Rahrig S, Kunz D, et al.: Platelet concentrates derived from buffy coat and apheresis: biochemical and functional differences. Transfus Med 2002; 12:317–324
    • (2002) Transfus Med , vol.12 , pp. 317-324
    • Böck, M.1    Rahrig, S.2    Kunz, D.3
  • 24
    • 62949132847 scopus 로고    scopus 로고
    • Evaluation of in vitro storage properties of prestorage pooled whole blood-derived platelets suspended in 100 percent plasma and treated with amotosalen and long-wavelength ultraviolet light
    • Wagner SJ, Skripchenko A, Myrup A, et al.: Evaluation of in vitro storage properties of prestorage pooled whole blood-derived platelets suspended in 100 percent plasma and treated with amotosalen and long-wavelength ultraviolet light. Transfusion 2009; 49:704–710
    • (2009) Transfusion , vol.49 , pp. 704-710
    • Wagner, S.J.1    Skripchenko, A.2    Myrup, A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.